These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Hepatitis caused by various derivatives of erythromycin]. Funck-Brentano C; Pessayre D; Benhamou JP Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792 [No Abstract] [Full Text] [Related]
6. Therapeutic doses of erythromycin esteolate is not cholestatic in rats in vivo. Fiebiger I; Anwer MS; Hegner D Naunyn Schmiedebergs Arch Pharmacol; 1983 May; 322(4):295-7. PubMed ID: 6866136 [TBL] [Abstract][Full Text] [Related]
7. [Effect of pretreatment with bacterial endotoxin on erythromycin estolate-induced cholestasis]. Adinolfi L; Perna P; Gaeta GB; Utili R Boll Soc Ital Biol Sper; 1981 Apr; 57(8):900-3. PubMed ID: 7023509 [TBL] [Abstract][Full Text] [Related]
8. [The 125-I-Rose Bengal test in pediatrics]. Lüders D Nucl Med (Stuttg); 1969 Apr; 8(1):46-60. PubMed ID: 5795622 [No Abstract] [Full Text] [Related]
9. [Alterations in liver function produced by erythromycin estolate in isolated and perfused rat liver]. Adinolfi L; Gaeta GB; Utili R Boll Soc Ital Biol Sper; 1980 Aug; 56(16):1621-5. PubMed ID: 7459082 [TBL] [Abstract][Full Text] [Related]
10. Erythromycin estolate to remain on market. FDA Drug Bull; 1982 Aug; 12(2):14. PubMed ID: 7141171 [No Abstract] [Full Text] [Related]
11. Characterization of the effects of erythromycin estolate and erythromycin base on the excretory function of the isolated rat liver. Gaeta GB; Utili R; Adinolfi LE; Abernathy CO; Giusti G Toxicol Appl Pharmacol; 1985 Sep; 80(2):185-92. PubMed ID: 2992120 [TBL] [Abstract][Full Text] [Related]
12. Fecal excretion of Rose bengal I 131 in the diagnosis of obstructive jaundice in infancy with special reference to biliary atresia. Maksoud JG; Thom AF; Kieffer J; Carvalho Pinto VA Pediatrics; 1971 Dec; 48(6):966-9. PubMed ID: 5129455 [No Abstract] [Full Text] [Related]
13. [Hepatocellular jaundice due to erythromycin estolate]. Zlotnick A Harefuah; 1978 Aug; 95(3-4):127-8. PubMed ID: 700498 [No Abstract] [Full Text] [Related]
14. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Keeffe EB; Reis TC; Berland JE Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110 [TBL] [Abstract][Full Text] [Related]
15. FDA begins proceedings to remove erythromycin estolate from market. FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836 [No Abstract] [Full Text] [Related]
16. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Zafrani ES; Ishak KG; Rudzki C Dig Dis Sci; 1979 May; 24(5):385-96. PubMed ID: 456225 [TBL] [Abstract][Full Text] [Related]
17. [The 125-I rose bengal test in jaundice with occlusion symptoms. 3. Measurements of radioactivity in the stool and urine of children (excretion test)]. Lüders D Z Kinderheilkd; 1969; 105(4):273-83. PubMed ID: 5808228 [No Abstract] [Full Text] [Related]
18. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver. Gafter U; Mandel EM; Weiss S; Djaldetti M N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477 [No Abstract] [Full Text] [Related]
19. Risk-benefit equation for erythromycin estolate. LeBel M Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788 [No Abstract] [Full Text] [Related]